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Whole genome and whole exome sequencing technologies are being increasingly
used in research. However, they have the potential to identify incidental findings (IF),
findings not related to the indication of the test, raising questions regarding
researchers’ responsibilities toward the return of this information to participants. In
this study we discuss the ethical considerations related to the return of IF to research
participants, emphasizing that the type of the study matters and describing the
current practice standards. There are currently no legal obligations for researchers to
return IF to participants, but some viewpoints consider that researchers might have an
ethical one to return IF of clinical validity and clinical utility and that are actionable.
The reality is that most IF are complex to interpret, especially since they were not the
indication of the test. The clinical utility often depends on the participants’
preferences, which can be challenging to conciliate and relies on participants’
understanding. In summary, in the context of a lack of clear guidance, researchers
need to have a clear plan for the disclosure or nondisclosure of IF from genomic
research, balancing their research goals and resources with the participants’ rights
and their duty not to harm.
Introduction
Landmark advances in science are often accompa-
nied by ethical challenges. During the past decade,
new methods for massively parallel sequencing have
been developed, computational approaches have
advanced, and there has been an increased availability
of large public sequencing datasets. As a result, whole
genome and whole exome sequencing (WGS/WES)
technologies have emerged as useful tools in both
research and clinical molecular diagnostics. WGS/
WES facilitates the sequencing of large regions of the
genome with a timely turnaround, and they are
increasingly affordable.1 The potential uses for
WGS/WES in medical genomics research are rapidly
expanding. In the past few years, the technology has
allowed the discovery of new genes and new
mechanisms, unraveling the genetic cause of single
gene and complex disorders where conventional
sequencing methods have failed in the past.2–5 This
is an exciting time for ophthalmic genomic research as
these techniques are now becoming increasingly used.
However, because WGS/WES are less targeted than
conventional genetic testing, they generate a vast
amount of genomic data well beyond what has been
generated by traditional targeted genetic approaches,
including the potential for incidental findings (IF). As
a result, complex ethical questions arise and challenge
the researchers’ responsibilities regarding disclosure
of these data to research participants. Although not
the topic of this paper, the same ethical issues apply to
genome-wide association studies, which also have the
potential to identify IF.6 In this paper, we discuss the
elements to consider when debating the return of
genomic IF generated from WGS/WES in a research
setting.
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Findings from WGS/WES can be broadly classified
in two categories: (1) the pertinent or primary findings
that are results relevant to the indication for which the
test was ordered and (2) unsolicited, secondary or
incidental findings that are results that are not related
to the primary indication of the test and may or may
not be relevant to the patient’s health (for example a
variant related to cancer identified through the conduct
of a study on the genetic causes of congenital
glaucoma). There is presently a great deal of contro-
versy over how IF should be handled in research:
which IF, if any, should be returned to participants
and how they should be returned.7–13 This debate has
been described by Wolf et al.14 as a problem of
translational research, when findings from research
have some potential clinical utility and impact on
clinical management.
The arguments in favor and against the return of
IF to research participants are outlined in Table
1.9,13,15–18 When evaluating whether IF should be
returned to participants, researchers need to consider
the type of the study, the practice standards and
ethical approvals in place, the analytical and clinical
relevance of the findings, and the participant’s
preferences in relation to return of results with
specific reference to the research consent documents.
Research Versus Clinical Settings
The context in which the return of individual
genomic research results is discussed does matter.19,20
The distinction between research and clinical care is
important because the underlying key principles are
different. The goal in research is to generate data for a
communal benefit, whereas in clinical care the
individual patient’s needs and benefits prevail. As a
result, the rights and duties of the individuals
implicated are different.21–23 However, the boundary
between clinical and research settings can be blurred,
especially when the research participants are patients
and when the researcher could also be their clinician,
making it harder to distinguish the responsibilities of
each person.16,22 This is a complex area, and the
distinctions are often poorly understood by patients
and health care workers generally. Even within the
research context, there are nuances, depending on the
circumstances, including the type of WGS/WES
performed, and the social context in which they take
place.19 Researchers’ obligations toward participants
are defined by the consent form and the protocol
approved by institutional review boards (IRBs) or
their equivalents, the overriding duty to protect
participants from harm, and the respect of privacy
and confidentiality.24 It is suggested that rather than a
one-size fits all, a case-by-case (or disease-by-disease)
approach is required regarding factors such as degree
of vulnerability of the study cohort, depth of
researcher/participant relationship, and degree of
participant dependence.20
Existing Recommendations
Several recommendations have been published
regarding the return of IF in both clinical and
research settings (Table 2). In the clinical setting, on
one side of the spectrum, the American College of
Medical Genetics and Genomics (ACMG) published
a statement advocating for opportunistic screening
and recommended that variants from a list of 56
genes associated with 24 disorders with high pene-
trance and clinical actionability be actively looked
for and returned, regardless of the age of the
patient.25,26 In the wake of vocal criticism of its
position, the ACMG revised its recommendations to
allow patients to opt out of the analysis of medically
actionable genes when undergoing WGS/WES.26 On
the other end of the spectrum, the European Society
of Human Genetics, the Canadian College of
Table 1. Ethical Principles in Favor or Against the Disclosure of Incidental Findings to Research Participants
For Against
Availability of results Availability of results outside of research
Principle of beneficence Principle of nonmaleficence (do not harm)
Leads to positive health outcome Promotes therapeutic misconception
Respects participant autonomy Risk for social discrimination/stigmatization
Respects the right to know Respects the right not to know
Increases trust in research Burden on research infrastructure
Principle of reciprocity Emotional harm
Duty to rescue
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 Laboratories need to actively search for the specified types
of mutations in 56 genes associated with 24 conditions
with high probability of severe adverse outcome and
report them to the clinician. Variants to be reported need
to be known pathogenic or expected pathogenic.
25, 26
 This is done regardless of the indication of the test and
the age of the patient, but patients can opt out of the
analysis of the genes during the consent process.
European Society of Human
Genetics (Europe, 2013)
 The use of a targeted approach to avoid IF is
recommended, and variants with limited clinical utility
should be filtered out. The use of WGS/WES requires a
justification of necessity and proportionality.
27
 The detection of IF of serious health problems that are




 Genomic testing should have a sound evidence base, and
targeted analysis is recommended.
28
 Clinicians should use standard practices in deciding
whether to return IF as long as the policy is clearly




 Genome-wide sequencing should only be considered when
proved useful in the evaluation process and a selective
filtering process is recommended.
29
 Should IF be detected, the patient should be given the
option to receive them or not prior to testing.
Research setting
National Heart Lung and
Blood Institute (USA, 2010)
 Genetic research results should be offered if the findings
have important health implications, are actionable and
analytically valid, comply with all applicable laws, and the
study participant has opted to receive them.
30
 Genetic research results may be returned if the potential
benefits outweigh the risks from the participant’s
perspective, the IRB has given approval, the findings are
analytically valid, they comply with all applicable laws, and
the study participant has opted to receive them (includes




 Researchers have an obligation to disclose to the
participants any material IF discovered during the course
of the research defined as having significant welfare
implications for the participant, as long as the participant
consented and the disclosure plan has been approved by
an IRB.
31
 Exception to the obligation to disclose can be requested
based on the impracticability or impossibility of disclosure
(undue hardship or onerousness jeopardizing the conduct
of the research).
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Medical Geneticists, and the Royal College of
Pathologists of Australasia encouraged caution and
recommended a targeted approach to the clinical
question to avoid the detection of IF.27–29 In the
research setting, the guidelines vary from defining
which IF should or may be returned30–34 to
recommendations that do not advocate for or refrain
from looking for IF, but frames how IF should be
returned if feasible.24,35,36
Return of Incidental Genetic Findings
in the Context of Eye Diseases
Although still disputed, there is a viewpoint that
even if researchers have no legal obligation, they
could have an ethical obligation to return genomic
variants that are of clinical validity (the variant is
known to be associated with a particular disease),
have clinical utility (the likelihood of a positive
health outcome), and are actionable (medical actions
can be taken to decrease the risk).8,13,30,34,37,38 As an
example, clinical validity would be low for genetic
variants associated with macular degeneration be-
cause of the weak correlation between specific
genotypes and visual outcome,39 but would it be
higher for disease-causing variants in the MYOC
gene associated with glaucoma and high pene-
trance.40 Similarly, retinitis pigmentosa (RP) dis-
ease-causing variants would currently be of limited
clinical utility due to the lack of available treatments.
This may change with the advent of gene therapy for
retinal dystrophies. Predictive genetic testing for RP
family members is a controversial topic.41 There is
some evidence that taking high doses of vitamin A
supplements may slow the progression of RP.42 A
patient may be symptomatic of RP, having nyctalo-




the Study of Bioethical
Issues (USA, 2012, 2013)
 Researchers should develop a plan to manage IF, which
should be approved by an IRB. Participants should be
informed of whether and how they might opt out of




 Research findings that are validated, scientifically relevant,
clinically significant, severely or moderately life threatening,
and clinically actionable should be returned with the
participant’s consent.
32
Network of Applied Genetic
Medicine (Canada, 2013)
 IF should be offered when they are scientifically and
clinically valid, have clinical utility, exceptions and
considerations related to the research context have been
weighted, IRB approval has been obtained, participant has
consented, and the result has been confirmed.
33
 IF may be offered if they are scientifically and clinically
valid, the benefits of return surpass the risks, IRB approval
has been obtained, participant has consented, and the







 Analytically and clinically IF that are actionable should be
offered to research participants if they agreed to the
return of results. Participants have the right to refuse any
results that are offered.
 Researchers do not have a duty to look for actionable IF.
34
National Health and Medical
Research Council (Australia,
2015)
 When the return of IF is feasible and the results are
adequately validated, participant should have the
autonomy to decide whether or not to request the return
of IF.
24
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would then alert them to their symptoms to justify
further diagnostic testing with visual fields, an
electroretinogram, and dark adaptation. Finally,
diagnosis of RP in young adults helps ensures safety
with driving and allows reproductive choices before
they have children. Genetic variants known to cause
retinoblastoma or choroidal melanoma would have a
stronger clinical utility based on their actionability
and the importance of early diagnosis. Information
related to reproductive or personal utility has
received much less consensus for disclosure. Overall,
the consensus reached refers to situations where the
potential benefits outweigh the potential harm for
the participant and the findings reach a relevant
threshold of validity and medical significance.43
Despite the endorsement of clinical validity,
clinical utility, and actionability for the return of IF,
the definition of each criterion has been relatively
inconsistent and is based on a range of different
interpretations.43 The reality is that many IF are
actually of unknown or dubious significance and
therefore not interpretable. Additionally, the meaning
of a pathogenic variant can differ between different
family members. Across the world it is generally
accepted that children should not be tested for adult-
onset conditions unless there is an immediate medical
benefit. When research involving children discovers
results related to adult predisposition conditions that
can be clinically relevant to the parents well before it
will have a clinical impact on the child, the question
has been raised whether these results should be
disclosed to the parents.44 Finally, an area that has
received little discussion is the lack of empirical
evidence regarding the clinical utility of most IF in
routine testing. Most data on disease-causing variants
have been collected using cohorts of affected individ-
uals, which can result in an overestimation of the
penetrance and expressivity45 and limit the extrapo-
lation to low-risk populations. The sensitivity and
specificity of any genetic test is only as strong as the
indication for the test. Along the same lines, the US
Preventive Services Task Force has recommended
against routine genetic testing for BRCA-related
cancer.46 Overall, researchers need to think about
how the information can be used for patients’ better
health and the potential to do more clinical harm than
good.
Prevalence of IF
Undoubtedly, WGS/WES will discover clinically
actionable variants in research participants. The
ACMG statement anticipated medically relevant IF
in 1% of sequencing reports.25 Based on a mathemat-
ical model and using the ACMG list, Ding et al.47
predicted IF in 2.7% of screened participants. Two
recent studies reported pathogenic variants from the
ACMG list among 0.9% to 1.7% of individuals,48,49
while others have reported prevalence of up to 12%
for variants of various clinical utility.50–53 The
difference between the studies can be attributed to
the cohort selection, the pathogenicity classification
criteria of variants, and the inclusion of conditions
and genes based on the definition of clinical utility.
When including variants associated with carrier status
of newborn diseases, risk factors for macular degen-
eration, and drug response, Tabor et al.54 demon-
strated that every exome would contain variants of
potential clinical utility. Furthermore, the prevalence
of clinically actionable findings is expected to increase
in the future with the improved accuracy of variant
annotation of genomic databases, better understand-
ing of the genetics of diseases, and development of
therapies.
Practical Considerations in the Return
of Research Results
Additional factors for the potential return of IF to
research participants must be considered. Most
research laboratories are not accredited to report
findings that could be used in clinical management.
The analytical validity of genetic variants identified
through WGS/WES in a research setting is not
reliable or robust enough to be reported. Validation
in an accredited laboratory and assessment for clinical
validity and significance by competent and accredited
professionals has been strongly advocated for disclo-
sure.24,30,32–34 Researchers often have a lack of
expertise for results or conditions that are outside
the scope of their research. As a result, posttest
counseling and medical follow-up needs to be
provided by trained professionals. Many have argued
that the requirements for the return of IF take
substantial time, effort, and resources that would
put an unsustainable burden on the research enter-
prise and move resources away from the primary
research.15,16,55,56 Substantial resources are required
for each of these steps, and current research funding is
typically not allocated to conduct this activity. One
study suggested a framework by which the clinical
setting would take care of those steps, ensuring the
distinction between research and clinical care re-
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mains.57 However, this option would move the
burden to the clinical setting, which would equally
struggle to sustain this workload.
Participants’ Perspectives and
Understanding
All guidelines recognize that the participants’
preferences need to be taken into account. Whenever
possible, participants should be informed of the
possibility of return of IF and the potential risks
and benefits, and they should be able to opt out of its
return.8,24,30,33,34,58 Participants’ familial, cultural,
and religious beliefs also need to be acknowledged.
Different models of consent59,60 and dynamic return
of results61,62 have been proposed to address the
complexity of the return of IF. To give informed
consent for every eventuality is impossible, and
studies have shown that categorizing the results
potentially returned facilitates the process.38,63
Respecting participants’ preferences can also pose
some challenges. In some situations, further investi-
gations of the participant and his or her family,
necessitating recontact, can be required to ascertain
the pathogenicity of a variant, making it difficult to
respect an individual’s wishes to learn only about
clinically significant variants.64 Historically, IF were
not always addressed properly in consent forms,
which creates issues for disclosure. Published guide-
lines have discussed whether the absence of reference
to IF disclosure in the consent form would prevent
their return and to what extent researchers can respect
participants’ wishes of not knowing IF of clinical
significance.24,30,34,65 Consultation with IRBs has
been advised in these situations.
Most studies evaluating the intention to receive
results among research participants66–71 or the
general public in hypothetical scenarios18,67,72–74
have shown that the majority wish to receive results,
regardless of the clinical validity and utility.
However, previous studies have often shown that
patients who expressed interest in obtaining results
do not always get tested, and even though the
uptake of genetic testing is higher for conditions
with preventive measures, it is still lower than
expected based on intentions.75–77 Moreover, indi-
viduals make different choices depending on what is
at stake and on the framing of the options,
emphasizing the difficulty of explaining the com-
plexity and uncertainty of research findings.78 The
issues surrounding IF are complex and take time to
explain and process. Tabor et al. evaluated a
protocol for obtaining informed consent for WGS
in two families that was nine pages long and took 2
to 3 hours.79 Although both families complained
about the length of time and the complexity of the
process, they both recognized the extent of the scope
of information that needed to be covered in order
for them to make informed decisions regarding the
return of IF. Few studies have reported what
patients really understood of the actual impact of
reporting or evaluated their experience of receiving
IF and the potential psychological harm.80 More
empirical data are needed on the actual benefits or
harm of receiving IF and the true understanding of
participants in regard to IF.
Researchers’ Perspectives
Genetic professionals and researchers are gener-
ally supportive of the disclosure of actionable IF but
are usually less so with results pertaining to
untreatable conditions, adult-onset conditions for
pediatric participants, or variants with lower clinical
validity and utility.56,74,81–84 Surveys among re-
searchers showed that although the majority are in
favor of returning highly penetrant, clinically ac-
tionable results, they also feel that it would be a
burden on researchers.74,82
Integrating the opinions of both stakeholders and
participants is vital in developing an effective plan for
the return of IF, but the discrepancies between what
results researchers and participants believe should be
disclosed might pose a challenge in balancing the
integrity of participant autonomy with researcher’s
decisions. Increasingly, particularly in light of the
growing discourse supporting disclosure, there is need
to ensure that participants’ expectations are carefully
managed during the informed consent process and
through clear information in the information sheet
and consent form as to what, if any, results will or
may be returned.
Incidental Genetic Findings: A Duty to
Find and Recontact?
If there is a duty for researchers to report IF, some
have questioned whether there could also be a duty to
actively look for IF since researchers have access to
the genomic data. Studies so far have concluded that
researchers do not have an obligation to look for
IF.34,56,65 The rationale is that it would blur the
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distinction between research and clinical care, create
clinical responsibilities for researchers, and accentuate
therapeutic misconception—the notion that research
will benefit individuals.22 Similarly, Gliwa et al.55
concluded that at present, although there could be
benefits for participants, and researchers are in a
unique position to access these data, the burden on
the research is too extensive for researchers to actively
look for IF. However, they argued that in the future,
if the analysis process becomes more efficient and if
WGS/WES are not yet implemented as a standard of
care in clinical care, researchers could face an
obligation to look for IF.
Similarly, knowledge about disease associations
will evolve over time, and variants are likely to be
interpreted differently.85 This raises the issue of a
potential duty to recontact research participants in
the light of new information. The question of
recontact could also apply to IF related to adult-
onset conditions identified in children. Most guide-
lines recommend that researchers do not have to
return IF beyond the termination of research fund-
ing.30,34 Indeed, even in the clinical setting it is
recognized that there must be limits on the duty to
recontact in the context of WGS/WES given the vast
amount of data potentially available.23 The preferable
approach is to explain to patients the fast-moving
nature of this area and put the onus on them to
recontact in the future if they want to find out if any
new information has come to light.
The Importance of Implementing a
Disclosure Plan
In the context of a lack of clear policies,
researchers need to implement a plan for managing
genomic data.30,31,33,34,65 The plan should describe the
type of results that could be disclosed, the modalities
of communication (who would disclose results, to
whom, when, how), and what should be discussed
during the consent process. Different frameworks for
the return of results have been proposed in the
literature: policy of no disclosure, disclosure of IF of
clinical utility and actionability only, disclosure of all
IF, return of all genomic data without interpretation,
and participant decides which IF would be re-
turned.8,13,16,32,37 Obviously, the frameworks provid-
ing more autonomy to participants also put
additional burden on the research infrastructure.
Another suggested approach has been to apply filters
during the analysis stage to hide unwanted results to
minimize the potential for IF.27,86 This strategy has
the benefit of limiting IF of potential clinical utility
and minimizing the burden on the research infra-
structure. Ultimately, the feasibility, cost, and conse-
quences of each approach need to be balanced.
Finally, IRBs oversee research involving human
subjects. They are in a unique position to provide
valuable insight in reviewing the disclosure plan to
research participants and participate in the develop-
ment of policies and guidelines.8,30,87
Conclusion
In summary, there is a lack of definite guidance
regarding the return of personal genomic research
results. At present, there is no legal obligation for
researchers to return IF from WGS/WES, but the
emerging view is that there might be an ethical one.
However, many have raised concerns about the
impact such obligation would have, and the feasibility
of such return is debated, with many arguing that the
burden on the research infrastructure would be too
significant. In any case, adopting a plan for the return
of IF needs to take into account the nature of the
research, the relationship between the researcher and
the participants, the nature of the informed consent,
and the duty to do no harm. Ultimately, even in the
case of an ethical obligation, the decision is at the
researcher’s discretion, with the support of IRBs,
recognizing that the participants’ rights need to be
balanced with the research goals. There is an evolving
need to develop stronger frameworks and guidance to
assist researchers in clarifying their responsibilities
toward the management and return of IF, particularly
in the view that the genetic landscape is continuously
expanding.
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